PAWI-2 is a p53 activator and Wnt inhibitor; it inhibits KRAS-independent β3-KRAS signaling; selectively inhibits TBK1 phosphorylation; activates apoptosis (via caspase-3/7 activation) and induces PARP cleavage; promotes nucleolar translocation of nucleostemin, leading to G2/M cell cycle arrest; reverses cancer stem cell properties in integrin β3-KRAS-dependent human pancreatic cancer stem cells (hPCSCs) and overcomes drug resistance; suppresses tumor growth of hPCSCs in orthotopic xenograft mouse models.